The global calming and sleeping products market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). With the arrival of modernization and a sedentary lifestyle, there has been registered numerous cases of sleep related disorders. Calming and sleeping products lessen anxiety and tension by inducing sedatives and a hypnotic effect on the body. They act by calming the central nervous system, and therefore are used to treat insomnia, sleep apnea, and other sleep related disorders. Various innovative solutions in the form medications as well as devices have been introduced to combat these disorders. Therefore, the rising incidences of various sleep related disorders is anticipated to boost the demand for calming and sleeping products across the globe. Adding to this, the growing prevalence of neurological disorders where improper sleep is an underlying cause, is further likely to add up to the market growth globally.

Various other factors that are responsible for the market growth included the hectic and stressful life, coupled with reduced sleep time owing to digital communication, games, work, and social responsibilities. Another, key trend observed includes the growing trend of late night coffee and tea consumption. This, however, leads to a disruption in sleeping patterns that calls for solutions such as the calming and sleeping products. In addition, the rising prevalence of sleep disorders such as insomnia, sleep apnea, sleep walking, and bruxism, among others is anticipated to propel the market growth.

Some key players operating in the market include Sanofi S.A., Koninklijke Philips N.V., and Natus Medical Inc., among others. The market players are focusing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships and collaborations, new product launches and development in the existing product portfolio, and so on. For instance, in July 2021, Sanofi received the US FDA approval for fexinidazole to treat a type of sleeping sickness, also called Human African trypanosomiasis. The US regulator indicated fexinidazole as a 10-day once-a-day all-oral treatment for Trypanosoma brucei gambiense in patients aged six years and above, weighing at least 20kg. Fexinidazole is said to be the first all-oral treatment for both the first and the second stages of the disease, where parasites cross the blood-brain barrier, causing neuropsychiatric symptoms.

Market Coverage

    • The market number available for – 2020-2027

    • Base year- 2020

    • Forecast period- 2021-2027

    • Segment Covered- 

o By Product Type

o By Application

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

    • Competitive Landscape:  Sanofi S.A., Koninklijke Philips N.V., and Natus Medical Inc., among others.

Key questions addressed by the report

    • What is the market growth rate?

    • Which segment and region dominate the market in the base year?

    • Which segment and region will project the fastest growth in the market?

    • How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

    • Who is the leader in the market?

    • How are players addressing challenges to sustain growth?

    • Where is the investment opportunity?

Global Calming and Sleeping Products Market Report by Segment

By Product Type

    • Medication

    • Sleep Laboratories

    • Sleep Apnea Devices

    • Mattresses and Pillows

    • Others

By Application

    • Insomnia

    • Sleep Apnea

    • Restless Leg Syndrome (RLS)

    • Bruxism

    • Narcolepsy

    • Sleepwalking

    • Others

Global Calming and Sleeping Products Market by Region

North America       

    • US

    • Canada

Europe

    • Germany

    • UK

    • France

    • Spain

    • Italy

    • Rest of Europe

Asia-Pacific    

    • China

    • Japan

    • India

    • Rest of Asia-Pacific

Rest of the World

    • Latin America

    • Middle East and Africa